Analysts think CTXR stock price could increase by 351%
Aug 01, 2024, 6:26 AM
-37.16%
What does CTXR do
Citius Pharmaceuticals, Inc., headquartered in Cranford, New Jersey, specializes in developing and commercializing critical care products focusing on oncology and anti-infectives, including notable products like Mino-Lok and I/ONTAK. Their diverse portfolio also includes treatments for hemorrhoids, post-surgery infections, and acute respiratory disease syndrome through products like Halo-Lido and NoveCite.
5 analysts think CTXR stock price will increase by 350.58%. The current median analyst target is $4.08 compared to a current stock price of $0.91. The lowest analysts target is $4.04 and the highest analyst target is $6.30.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
